Form 4: Amicus Therapeutics CEO Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Amicus Therapeutics' CEO, Bradley L. Campbell, exercised stock options and sold a small portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 19, 2025, Bradley L. Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 400 shares of common stock at a price of $9.03 per share.
- Simultaneously, Campbell sold 400 shares of common stock at a price of $10 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these transactions, Campbell directly owns 1,150,657 shares of Amicus Therapeutics common stock and 99,600 stock options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Future Outlook
There is no future outlook provided in this document.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize Rule 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The sale is not necessarily indicative of the executive's sentiment about the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date the reporting person adopted the Rule 10b5-1 trading plan |
| 02/19/2025 | Date of stock option exercise and sale of shares |
| 01/04/2026 | Expiration date of the stock options |
| 02/21/2025 | Date of Form 4 filing |
Keywords
Amicus Therapeutics, Bradley L. Campbell, stock options, Form 4, Rule 10b5-1, insider trading, securities, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.